Author

Leticia Colyn

Max Planck Institute of Molecular Cell Biology and GeneticsORCID 0000-0002-7403-9149Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Amaya López-PascualiD· 2 shared Borja Castelló-UribeiD· 2 shared Carmen BerasainiD· 2 shared Elena Adán-VillaescusaiD· 2 shared Emiliana Valbuena-GoiricelayaiD· 2 shared Eva SticováiD· 2 shared Iker UriarteiD· 2 shared Jasmin ElurbideiD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Amaya López-PascualORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma

Amaya López-Pascual, Jasmin Elurbide, Emiliana Valbuena-Goiricelaya, Maria Ujue Latasa, Elena Anaya, Elena Adán-Villaescusa, Borja Castelló-Uribe, Luz Andrea Martínez‐Pérez, Iker Uriarte, María Arechederra, Sergio Ciordia, Fernando José Corrales, Pavel Strnad, Soňa Fraňková, Eva Sticová, , Matias Antonio Avila

This study identifies altered epigenetic regulators and metabolic genes in cholangiocarcinoma, linking them to poor prognosis and metabolic-epigenetic crosstalk.

Frontiers in Cell and Developmental Biology · Jun 4, 2026Peer-reviewedCancer Biology

Protein arginine-methyltransferase 1 (PRMT1): a new pharmacological target in cholangiocarcinoma

Emiliana Valbuena-Goiricelaya, Jasmin Elurbide, Maria Ujue Latasa, Amaya López-Pascual, Iker Uriarte, Leticia Colyn, Patrícia Inácio, Robert Arnes‐Benito, Elena Adán-Villaescusa, Borja Castelló-Uribe, Barbara Franceschini, Flavio Milana, Pavel Strnad, Soňa Fraňková, Eva Sticová, , Matias Antonio Avila

This study identifies PRMT1 as a critical driver of cholangiocarcinoma growth and immune evasion, showing its inhibition enhances antitumor immunity and synergizes with immunotherapy.

bioRxiv · May 29, 2026 · PreprintCancer Biology